Clinical Trial Update: Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated depsipeptide (romidepsin) for cutaneous T-cell lymphoma and peripheral T-cell lymphoma. The trial has completed with results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• Istodax (romidepsin) (romidepsin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Cutaneous T Cell Lymphoma, Peripheral T Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2016-02-12